Key statistics dashboard for Halozyme Therapeutics, Inc. (HALO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20).
Stock Data
| Price | $106.99 |
| Market Cap | $12.7B |
| Enterprise Value | $14.85B |
| Beta | 1.03 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 30.81 |
| Price / Book | 88.60 |
| P/S | 7.73 |
| EV/EBITDA | 20.79 |
| EV/Sales | 8.92 |
| EV/FCF | 18.41 |
| P/FCF | 15.95 |
| Earnings Yield | 3.25% |
| FCF Yield | 6.27% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 78.18% |
| EBIT Margin | 36.28% |
| EBITDA Margin | 42.92% |
| Operating Margin | 56.77% |
| Net Margin | 24.86% |
| Return on Equity | 180.63% |
| Return on Assets | 16.05% |
| Return on Invested Capital | 27.42% |
| Return on Capital Employed | 42.30% |
Financial Health
| Current Ratio | 2.71 |
| Quick Ratio | 2.31 |
| Cash Ratio | 0.47 |
| Debt / Equity | 14.95 |
| Debt / Assets | 83.29% |
| Net Debt / EBITDA | 2.78 |
| Interest Coverage | 46.52 |
Per-Share Data
| Revenue per share | 14.19 |
| Book Value per share | 1.22 |
| Cash per share | 1.97 |
| FCF per share | 6.87 |
| Tangible Book Value per share | -11.60 |
| Dividend per share | 0.00 |
Related companies: ABVX · ATR · CAI · CORT · CYTK · GRFS · HSIC
Explore sector: Healthcare · Biotechnology
More sections of HALO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks